Gangliosides from human melanoma immunomodulate response of T cells to interleukin-2
- 31 January 1988
- journal article
- research article
- Published by Elsevier BV in Cellular Immunology
- Vol. 111 (2), 410-419
- https://doi.org/10.1016/0008-8749(88)90104-9
Abstract
The gangliosides expressed by normal melanocytes are predominantly GM3 (>90%) and GD3 (N-acetylgalactosamine. Since different gangliosides can up-regulate and down-regulate lymphocyte responses to IL-2, the ganglioside phenotype of melanoma cells may play a major role in determining whether an individual tumor causes immune stimulation or suppression.This publication has 19 references indexed in Scilit:
- GlycosphingolipidsScientific American, 1986
- Direct Evidence That Endogenous G M1 Ganglioside Can Mediate Thymocyte ProliferationScience, 1985
- Immunogenicity of melanoma‐associated gangliosides in cancer patientsInternational Journal of Cancer, 1985
- Modulation of the immune response by gangliosides. Inhibition of adherent monocyte accessory function in vitro.JCI Insight, 1984
- Interleukin 2: the molecule and its functionImmunology Today, 1984
- Binding of interleukin 2 to gangliosidesFEBS Letters, 1984
- Gangliosides of normal and neoplastic human melanocytesBiochemical and Biophysical Research Communications, 1984
- Lipid Composition of Human Malignant Melanoma Tumors at Various Levels of Malignant GrowthEuropean Journal of Biochemistry, 1979
- Alteration of gangliosides in plasma and red cells of humans bearing melanoma tumorsBiochemical and Biophysical Research Communications, 1978
- Selective in Vitro Growth of T Lymphocytes from Normal Human Bone MarrowsScience, 1976